文献速递瓣膜外科

第三代生物瓣膜在主动脉位置的十年临床与超声心动图随访

Ten-year clinical and echocardiographic follow-up of third-generation biological prostheses in the aortic position.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-10-26

该研究纳入2010至2012年连续689例使用PERIMOUNT Magna Ease(PME)瓣膜行主动脉瓣置换术的患者,完成10年临床随访,并在1、5、10年分析超声心动图数据。10年结构性瓣膜退化(SVD)≥2级和再次手术的累积发生率分别为3.6%和1.9%,小于65岁患者SVD≥2级和再次主动脉瓣置换的累积发生率高于65至75岁和大于75岁患者。结论认为PME长期耐久性很好,可考虑作为主动脉瓣置换的高性能第三代生物瓣膜之一。

要点

  • 10年SVD≥2级和再次手术累积发生率分别为3.6%和1.9%。
  • 小于65岁患者10年SVD≥2级累积发生率为9.7%,65至75岁为2.6%,大于75岁为2.7%(P = .013)。
  • 小于65岁患者10年再次主动脉瓣置换累积发生率为7.8%,65至75岁为3.3%,大于75岁为0.4%(P = .002)。

核心结论

  • PME瓣膜长期耐久性很好,可考虑作为主动脉瓣置换的高性能第三代生物瓣膜之一。

研究设计与样本

  • 2010至2012年连续689例患者使用PERIMOUNT Magna Ease(PME)瓣膜行主动脉瓣置换术,完成10年临床随访,超声心动图数据在1、5、10年分析,主要事件采用竞争风险分析。

主要发现

  • 10年SVD≥2级和再次手术的总体累积发生率分别为3.6%和1.9%。
  • 植入后早期即出现左心室逆重构,并在随访中得到确认。
  • 小于65岁患者10年SVD≥2级累积发生率为9.7%,65至75岁为2.6%,大于75岁为2.7%(P = .013)。
  • 小于65岁患者10年再次主动脉瓣置换累积发生率为7.8%,65至75岁为3.3%,大于75岁为0.4%(P = .002)。
  • 不同瓣膜尺寸类别(19-21-23 mm vs 25-27-29 mm)之间SVD和再次主动脉瓣置换无差异(P > .05)。

关键数值与推荐

  • SVD程度根据最新指南进行分类。
  • 按瓣膜尺寸(19-21-23 mm vs 25-27-29 mm)和年龄(<65岁 vs 65-75岁 vs >75岁)评估SVD、再次手术和心内膜炎的累积发生率。
  • 心内膜炎风险在各年龄组和尺寸组间相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: PERIMOUNT Magna Ease (Carpentier-Edwards; PME) prostheses have been widely implanted during the past decade for aortic valve replacement (AVR). Although promising results at midterm follow-up were reported, long-term outcome has yet to be confirmed. On this study we aimed to evaluate long-term results in terms of structural valve degeneration (SVD), major clinical outcomes, long-term hemodynamic valve performance, and left ventricular remodeling. METHODS: From 2010 to 2012, 689 consecutive patients underwent AVR with PME. Complete clinical 10-year follow-up was obtained. The degree of SVD was categorized on the basis of the latest guidelines. Echocardiographic data were analyzed at 1, 5, and 10 years. Competing risk analysis was performed for major events. Cumulative incidence of SVD, reoperation, and endocarditis were also assessed according to prosthetic sizes (19-21-23 mm vs 25-27-29 mm) and age (<65 vs 65-75 vs >75 years old). RESULTS: The overall cumulative incidence reported for SVD ≥2 and reoperation were 3.6% and 1.9% at 10 years, respectively. An early left ventricular reverse remodeling was noted after implantation and confirmed at follow-up. Patients younger than 65 years showed higher cumulative incidence of SVD ≥2 at 10 years compared with patients aged 65 to 75 and older than 75 years (9.7% vs 2.6% vs 2.7%; P = .013), as well as of redo AVR (7.8% vs 3.3% vs 0.4%; P = .002). There was no difference in terms of SVD and redo AVR for different prosthetic size categories (P > .05). The risk of endocarditis was similar among age and size groups. CONCLUSIONS: PME provides very good durability at long-term and could be considered one of the high performing third-generation bioprostheses for AVR.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Francica A, Benvegnù L, San Biagio L, et al. Ten-year clinical and echocardiographic follow-up of third-generation biological prostheses in the aortic position. J Thorac Cardiovasc Surg. 2022. PMID: 36404144. doi:10.1016/j.jtcvs.2022.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。